JAMA Network
About the study: The findings from this meta-analysis support TTR gene silencing for ATTR-CM. The attenuated benefit observed for patients receiving concomitant TTR stabilizer therapy may reflect residual differences in case mix, disease duration, or magnitude of TTR suppression or a true ceiling on additional benefit of gene silencing in the setting of background TTR stabilization.
Meeting Information: ESC 2026
This paper will be presented during European Society of Cardiology Congress in Munich, Germany.
Local Embargo Time: 14:30 (2:30 P.M.) CEST.
ESC Presentation: Julian Gillmore will simultaneously present the findings during the late-breaking clinical science session on cardiac amyloidosis in Ashgabat, Hall A3.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
